Colin Bristow
Stock Analyst at UBS
(1.54)
# 3,544
Out of 5,143 analysts
105
Total ratings
38.71%
Success rate
-7.25%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $9.34 | +7.07% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $461.14 | +18.40% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $129.11 | -13.25% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $75.56 | +5.88% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.69 | +35.50% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.47 | -31.97% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $26.02 | -34.67% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $343.60 | -7.16% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.81 | +120.99% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $25.89 | +8.15% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $111.11 | +8.00% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $172.62 | +17.02% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.84 | +769.57% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $749.33 | +46.66% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $21.37 | +681.47% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $1,078.52 | -61.06% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $12.08 | -83.44% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.15 | +737.21% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $216.15 | -32.45% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $54.50 | +37.61% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.12 | +1,126.42% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $6.30 | +42.86% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $9.34
Upside: +7.07%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $461.14
Upside: +18.40%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $129.11
Upside: -13.25%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $75.56
Upside: +5.88%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.69
Upside: +35.50%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.47
Upside: -31.97%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $26.02
Upside: -34.67%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $343.60
Upside: -7.16%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.81
Upside: +120.99%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.89
Upside: +8.15%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $111.11
Upside: +8.00%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $172.62
Upside: +17.02%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.84
Upside: +769.57%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $749.33
Upside: +46.66%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $21.37
Upside: +681.47%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $1,078.52
Upside: -61.06%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $12.08
Upside: -83.44%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.15
Upside: +737.21%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $216.15
Upside: -32.45%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $54.50
Upside: +37.61%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.12
Upside: +1,126.42%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $6.30
Upside: +42.86%